Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Objective Response Rate — .85 proportion of patients

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Objective Tumor Response — 0 participants

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Progression-Free Survival (PFS) — 8 years

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…